Drugs / SNV4818
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06736704 | Feb 2025 → Apr 2027 expected | cancer | Pikavation Therapeutics, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-24 | Synnovation Therapeutics, Inc. | Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors synnovationtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNV4818 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06736704 ↗ |
| Route | Oral | “taken orally” NCT06736704 ↗ |